The 2-oxopyrrolidinacetamide piracetam reduces infarct brain volume induced by permanent middle cerebral artery occlusion in male rats

被引:21
作者
Tortiglione, A [1 ]
Minale, M [1 ]
Pignataro, G [1 ]
Amoroso, S [1 ]
DiRenzo, G [1 ]
Annunziato, L [1 ]
机构
[1] Univ Naples Federico II, Sch Med, Nurosci Dept, Pharmacol Sect, I-80131 Naples, Italy
关键词
piracetam; pMCAO; infarct volume;
D O I
10.1016/S0028-3908(02)00093-X
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
In this study, the temporal development of focal cerebral infarction induced by permanent middle cerebral artery occlusion (pMCAO) and the effects of piracetam, a derivative of gamma-aininobutyric acid widely used in clinical practice as a nootropic agent, on infarct area and volume were investigated. pMCAO caused a cerebral infarct whose size progressively increased after 3, 6, 9, and 24 h. Piracetam (125 mg/ka i.p.), administered 6, 9, and 22 h after pMCAO, did not reduce pMCAO-induced brain infarct area size detected at the 24th hour. By contrast, when this agent was administered at the doses of 250 and 500 mg/kg, it caused a marked reduction of the infarct area size. This reduction was observed in almost every brain slice affected by pMCAO, although statistical differences (p <0.05) were detected in slices located at 3-5.5 mm posterior to the anterior pole in animals treated with 250 mg/kg piracetam and in slices located at 3.5-5 mm in those receiving 500 mg/kg. When the mean total volumes of brain infarct resulting from pMCAO were calculated, it was observed that in animals which had received piracetam (250 or 500 mg/kg) infarction volume was markedly (50%) and significantly (p <0.05) reduced in comparison with saline injected rats. Finally, piracetam (250 mg/kg administered i.p. 6, 9, and 22 h after the ischemic insult) significantly reduced brain infarct area evaluated 48 h and 7 days after pMCAO. (C) 2002 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:427 / 433
页数:7
相关论文
共 26 条
[11]  
GIURGEA C, 1970, REV NEUROL, V122, P484
[12]  
Giurgea C, 1976, CURRENT DEV PSYCHOPH, P222
[13]  
Heiss W- D, 1983, POSITRON EMISSION TO, P162
[14]   The role of piracetam in the treatment of acute and chronic aphasia [J].
Huber, W .
PHARMACOPSYCHIATRY, 1999, 32 :38-43
[15]   Beneficial effect of piracetam monotherapy on post-ischaemic palatal myoclonus [J].
Karacostas, D ;
Doskas, T ;
Artemis, N ;
Vadicolias, K ;
Milonas, I .
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 1999, 27 (04) :201-205
[16]  
KILIC E, 1999, OFFICIAL J INT SOC C, V19, P511
[17]   Attenuation of ischemic brain edema and cerebrovascular injury after ischemic preconditioning in the rat [J].
Masada, T ;
Hua, Y ;
Xi, GH ;
Ennis, SR ;
Keep, RF .
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 2001, 21 (01) :22-33
[18]   Effects of piracetam on membrane fluidity in the aged mouse, rat, and human brain [J].
Muller, WE ;
Koch, S ;
Scheuer, K ;
Rostock, A ;
Bartsch, R .
BIOCHEMICAL PHARMACOLOGY, 1997, 53 (02) :135-140
[19]   PIRACETAM-INDUCED CHANGES TO MEMBRANE PHYSICAL-PROPERTIES - A COMBINED APPROACH BY P-31 NUCLEAR-MAGNETIC-RESONANCE AND CONFORMATIONAL-ANALYSIS [J].
PEUVOT, J ;
SCHANCK, A ;
DELEERS, M ;
BRASSEUR, R .
BIOCHEMICAL PHARMACOLOGY, 1995, 50 (08) :1129-1134
[20]  
PLATT D, 1992, MED WELT, V43, P181